Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival

•Following contemporary primary therapy, 98% of women with stage II-IV LGSOC who relapsed did so within 5 years of diagnosis.•Fifty-one percent of women who received contemporary primary therapy had not relapsed at time of analysis.•This study delineates several clinicopathologic factors that may be associated with patient outcomes.